Skip to main content
Premium Trial:

Request an Annual Quote

Robert Strausberg, Craig Venter, Eric Eisenstadt, Marv Frazier, Julie Gross Adelson, Aimee Turner, Thomas Barnes, David Urdal, Mark Gabrielson, Jules Blake

Robert Strausberg has been named deputy director of the J. Craig Venter Institute as part of a broad reorganization of its two research divisions — the Institute for Genomic Research and the Center for the Advancement of Genomics — into several more tightly focused units.
The JCVI will now consist of 10 distinct research groups: Genomic Medicine, Infectious Disease, Synthetic Biology & Bioenergy, Plant Genomics, Microbial & Environmental Genomics, Pathogen Functional Genomics, Applied Bioinformatics, Research Informatics, Software Engineering, and a Policy Center.
Craig Venter will remain president and chairman of the institute, and Strausberg, who had been president of TCAG, has been named deputy director. Eric Eisenstadt, former vice president for research of TIGR, has been named deputy vice president for research.
Marv Frazier, former vice president for research at TCAG, is now the executive vice president for research. Julie Gross Adelson has been named general counsel, while Aimee Turner, formerly CFO at TIGR, is now CFO of the JCVI.

Gene Logic has appointed Thomas Barnes as senior vice president of discovery. In this position, Barnes will lead the company's drug-repositioning discovery efforts.
Barnes was a co-founder of the drug-repositioning initiative within Millennium Pharmaceuticals, which Gene Logic acquired in 2004.
Prior to joining Gene Logic, Barnes led Millennium's development and application of genomic technologies for downstream drug development. He has also held academic appointments at Harvard Medical School and McGill University.
He will take over the duties of Louis Tartaglia, senior vice president of drug repositioning at Gene Logic, who will resign on June 15 to become a partner in a venture capital firm. Tartaglia, who also co-founded the drug-repositioning service at Millennium, will continue to serve on a consulting basis as a senior advisor.
Gene Logic has also elected David Urdal and Mark Gabrielson to its board of directors.
Urdal is currently senior vice president and chief scientific officer of Dendreon, while Gabrielson is a co-founder, director, and CEO of Pulmatrix.
In addition, the company said that Jules Blake is retiring from the board of directors after serving on the board since 1994.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.